Terns Board Unanimously Recommends Shareholders Accept Merck's $53.00/Share Cash Tender Offer

summarizeSummary

Terns Pharmaceuticals' Board of Directors formally recommended shareholders tender their shares to Merck for $53.00 per share in cash, citing a substantial premium and immediate value realization.

check_boxKey Events

• Board Unanimously Recommends Tender Offer

  Terns' Board of Directors unanimously recommends that shareholders accept Merck's tender offer of $53.00 per share in cash for all outstanding shares.

• Significant Acquisition Premium

  The $53.00 per share offer represents a substantial premium of approximately 54% over the stock price on January 23, 2026, and 47% over the price on February 4, 2026, prior to Merck's initial proposal.

• Strategic Rationale for Sale

  The Board cited the immediate and certain cash value, the inherent risks of standalone drug development, and the lack of higher alternative offers after an extensive outreach process to potential bidders as key reasons for the recommendation.

• Insider Equity Compensation

  Executive officers and directors will receive approximately $255.76 million from the accelerated vesting and cash settlement of their in-the-money options and restricted stock units.

auto_awesomeAnalysis

This SC 14D9 filing provides the detailed rationale behind Terns Pharmaceuticals' Board of Directors' unanimous recommendation to accept Merck's tender offer. The Board emphasized the significant premium offered over recent trading prices, the certainty of cash value compared to the inherent risks of standalone drug development, and the extensive process undertaken to explore alternative strategic options. The offer price of $53.00 per share provides immediate liquidity and a substantial return for shareholders, particularly given the company's early-stage pipeline. The filing also details the financial interests of executive officers and directors, including accelerated vesting of equity awards, which were considered by the Board. This formal recommendation is a critical step in the acquisition process, following the definitive merger agreement announced on March 25, 2026, and the tender offer commencement on April 7, 2026.